Answers are grounded in this paper and cite their sources.
Background: Multiple myeloma (MM) is a malignant plasma cell disorder characterized by excessive bone resorption leading to osteolytic lesions and skeletal complications. Conventional imaging techniques often detect bone destruction at advanced stages, highlighting the need for reliable biochemical markers. Objective: To evaluate serum ICTP levels and investigate their association with osteolytic lesions and hematological and biochemical parameters in newly diagnosed Multiple myeloma patients. Methods: A cross-sectional analytical study was conducted on 40 newly diagnosed multiple myeloma patients and 30 age- and sex-matched healthy controls. Serum ICTP levels were measured using ELISA. Patients were categorized based on the presence of osteolytic lesions. Statistical analysis included independent t-test and Spearman correlation. Results: Serum ICTP levels were significantly higher in patients compared to controls (p<0.001). Patients with osteolytic lesions had significantly higher ICTP levels than those without lesions (p<0.001). ICTP showed a significant negative correlation with hemoglobin and positive correlations with urea, creatinine, and calcium (p<0.05). Conclusion: ICTP is a valuable biomarker reflecting bone resorption and disease severity in multiple myeloma and may aid in early detection of skeletal involvement.
No takes yet. Share an insight, caveat, or question.
Habeeb et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: